Skip to main content
Top
Published in: Alzheimer's Research & Therapy 6/2010

01-10-2010 | Review

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials

Authors: Joshua D Grill, Jason Karlawish

Published in: Alzheimer's Research & Therapy | Issue 6/2010

Login to get access

Abstract

Among the key challenges in Alzheimer's disease drug development is the timely completion of clinical trials. Unfortunately, clinical trials often suffer from slow or insufficient enrollment. Successful clinical trial recruitment describes a balance between expeditiously achieving full enrollment and ensuring an appropriate study sample. Investigators face a number of challenges to the successful negotiation of this balance. The failure to address these challenges means that drug development may take more time and money and that trial results may not adequately represent drug efficacy or may not be applicable beyond the study. We review the challenges to recruitment and retention in Alzheimer's disease clinical trials and present a framework to address them.
Literature
2.
go back to reference Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials. 1998, 19: 178-187. 10.1016/S0197-2456(97)00118-9.CrossRefPubMed Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials. 1998, 19: 178-187. 10.1016/S0197-2456(97)00118-9.CrossRefPubMed
3.
go back to reference Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed
4.
go back to reference Haidich AB, Ioannidis JP: Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. Am J Epidemiol. 2001, 154: 873-880. 10.1093/aje/154.9.873.CrossRefPubMed Haidich AB, Ioannidis JP: Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. Am J Epidemiol. 2001, 154: 873-880. 10.1093/aje/154.9.873.CrossRefPubMed
5.
go back to reference Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A: Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006, 367: 1057-1065. 10.1016/S0140-6736(06)68350-5.CrossRefPubMed Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A: Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006, 367: 1057-1065. 10.1016/S0140-6736(06)68350-5.CrossRefPubMed
6.
go back to reference Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000, 283: 1007-1015. 10.1001/jama.283.8.1007.CrossRefPubMed Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000, 283: 1007-1015. 10.1001/jama.283.8.1007.CrossRefPubMed
7.
go back to reference Gómez-Isla T, Blesa R, Boada M, Clarimón J, Del Ser T, Domenech G, Ferro JM, Gómez-Ansón B, Manubens JM, Martínez-Lage JM, Muñoz D, Peña-Casanova J, Torres F, TRIMCI Study Group: A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008, 22: 21-29.CrossRefPubMed Gómez-Isla T, Blesa R, Boada M, Clarimón J, Del Ser T, Domenech G, Ferro JM, Gómez-Ansón B, Manubens JM, Martínez-Lage JM, Muñoz D, Peña-Casanova J, Torres F, TRIMCI Study Group: A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008, 22: 21-29.CrossRefPubMed
8.
go back to reference Vozdolska R, Sano M, Aisen P, Edland SD: The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009, 6: 126-132. 10.1177/1740774509103485.PubMedCentralCrossRefPubMed Vozdolska R, Sano M, Aisen P, Edland SD: The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009, 6: 126-132. 10.1177/1740774509103485.PubMedCentralCrossRefPubMed
9.
go back to reference Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH: Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease: A Randomized Controlled Trial. JAMA. 2009, 302: 2557-2564. 10.1001/jama.2009.1866.PubMedCentralCrossRefPubMed Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH: Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease: A Randomized Controlled Trial. JAMA. 2009, 302: 2557-2564. 10.1001/jama.2009.1866.PubMedCentralCrossRefPubMed
10.
go back to reference Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009, 73: 2061-2070. 10.1212/WNL.0b013e3181c67808.PubMedCentralCrossRefPubMed Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009, 73: 2061-2070. 10.1212/WNL.0b013e3181c67808.PubMedCentralCrossRefPubMed
11.
go back to reference Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9: 363-372. 10.1016/S1474-4422(10)70043-0.CrossRefPubMed Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9: 363-372. 10.1016/S1474-4422(10)70043-0.CrossRefPubMed
12.
go back to reference Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348: 1333-1341. 10.1056/NEJMoa013128.CrossRefPubMed Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348: 1333-1341. 10.1056/NEJMoa013128.CrossRefPubMed
13.
go back to reference Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004, 291: 317-324. 10.1001/jama.291.3.317.CrossRefPubMed Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004, 291: 317-324. 10.1001/jama.291.3.317.CrossRefPubMed
14.
go back to reference Albert SM, Sano M, Marder K, Jacobs DM, Brandt J, Albert M, Stern Y: Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology. 1997, 49: 38-43.CrossRefPubMed Albert SM, Sano M, Marder K, Jacobs DM, Brandt J, Albert M, Stern Y: Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology. 1997, 49: 38-43.CrossRefPubMed
15.
go back to reference Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB: Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002, 59: 1737-1746. 10.1001/archneur.59.11.1737.CrossRefPubMed Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB: Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002, 59: 1737-1746. 10.1001/archneur.59.11.1737.CrossRefPubMed
16.
go back to reference Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R: Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994, 271: 1004-1010. 10.1001/jama.271.13.1004.CrossRefPubMed Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R: Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994, 271: 1004-1010. 10.1001/jama.271.13.1004.CrossRefPubMed
17.
go back to reference Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy GM, Olin JT, Regier D, Sano M, Mintzer JE: Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. Int Psychogeriatr. 2007, 19: 539-558. 10.1017/S104161020700511X.CrossRefPubMed Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy GM, Olin JT, Regier D, Sano M, Mintzer JE: Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. Int Psychogeriatr. 2007, 19: 539-558. 10.1017/S104161020700511X.CrossRefPubMed
18.
go back to reference Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, Hebert LE, Aggarwal N, Beckett LA, Joglekar R, Berry-Kravis E, Schneider J: Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003, 60: 185-189. 10.1001/archneur.60.2.185.CrossRefPubMed Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, Hebert LE, Aggarwal N, Beckett LA, Joglekar R, Berry-Kravis E, Schneider J: Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003, 60: 185-189. 10.1001/archneur.60.2.185.CrossRefPubMed
19.
go back to reference Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, Mayeux R: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001, 56: 49-56.CrossRefPubMed Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, Mayeux R: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001, 56: 49-56.CrossRefPubMed
20.
go back to reference Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010, 6: 158-194. 10.1016/j.jalz.2010.01.009.CrossRef Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010, 6: 158-194. 10.1016/j.jalz.2010.01.009.CrossRef
21.
go back to reference Karlawish JH, Casarett D, Klocinski J, Sankar P: How do AD patients and their caregivers decide whether to enroll in a clinical trial?. Neurology. 2001, 56: 789-792.CrossRefPubMed Karlawish JH, Casarett D, Klocinski J, Sankar P: How do AD patients and their caregivers decide whether to enroll in a clinical trial?. Neurology. 2001, 56: 789-792.CrossRefPubMed
22.
go back to reference Carr SA, Davis R, Spencer D, Smart M, Hudson J, Freeman S, Cooper GE, Schmitt FA, Markesbery WR, Danner D, Jicha GA: Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord. 2010, 24: 165-170. 10.1097/WAD.0b013e3181aba927.PubMedCentralCrossRefPubMed Carr SA, Davis R, Spencer D, Smart M, Hudson J, Freeman S, Cooper GE, Schmitt FA, Markesbery WR, Danner D, Jicha GA: Comparison of recruitment efforts targeted at primary care physicians versus the community at large for participation in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord. 2010, 24: 165-170. 10.1097/WAD.0b013e3181aba927.PubMedCentralCrossRefPubMed
23.
go back to reference Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007, 69: 2197-2204. 10.1212/01.wnl.0000271090.28148.24.CrossRefPubMed Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007, 69: 2197-2204. 10.1212/01.wnl.0000271090.28148.24.CrossRefPubMed
24.
go back to reference Lai JM, Hawkins KA, Gross CP, Karlawish JH: Self-reported distress after cognitive testing in patients with Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2008, 63: 855-859.PubMedCentralCrossRefPubMed Lai JM, Hawkins KA, Gross CP, Karlawish JH: Self-reported distress after cognitive testing in patients with Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2008, 63: 855-859.PubMedCentralCrossRefPubMed
25.
go back to reference Hirschman KB, Joyce CM, James BD, Xie SX, Karlawish JH: Do Alzheimer's disease patients want to participate in a treatment decision, and would their caregivers let them?. Gerontologist. 2005, 45: 381-388.CrossRefPubMed Hirschman KB, Joyce CM, James BD, Xie SX, Karlawish JH: Do Alzheimer's disease patients want to participate in a treatment decision, and would their caregivers let them?. Gerontologist. 2005, 45: 381-388.CrossRefPubMed
26.
go back to reference Sugarman J, Cain C, Wallace R, Welsh-Bohmer KA: How proxies make decisions about research for patients with Alzheimer's disease. J Am Geriatr Soc. 2001, 49: 1110-1119. 10.1046/j.1532-5415.2001.49218.x.CrossRefPubMed Sugarman J, Cain C, Wallace R, Welsh-Bohmer KA: How proxies make decisions about research for patients with Alzheimer's disease. J Am Geriatr Soc. 2001, 49: 1110-1119. 10.1046/j.1532-5415.2001.49218.x.CrossRefPubMed
27.
go back to reference Connell CM, Shaw BA, Holmes SB, Foster NL: Caregivers' attitudes toward their family members' participation in Alzheimer disease research: implications for recruitment and retention. Alzheimer Dis Assoc Disord. 2001, 15: 137-145. 10.1097/00002093-200107000-00005.CrossRefPubMed Connell CM, Shaw BA, Holmes SB, Foster NL: Caregivers' attitudes toward their family members' participation in Alzheimer disease research: implications for recruitment and retention. Alzheimer Dis Assoc Disord. 2001, 15: 137-145. 10.1097/00002093-200107000-00005.CrossRefPubMed
28.
go back to reference Elad P, Treves TA, Drory M, Verchovsky R, Klimovitsky S, Ben-Laish S, Yaron S, Ginzburg K, Korczyn AD: Demented patients' participation in a clinical trial: factors affecting the caregivers' decision. Int J Geriatr Psychiatry. 2000, 15: 325-330. 10.1002/(SICI)1099-1166(200004)15:4<325::AID-GPS117>3.0.CO;2-9.CrossRefPubMed Elad P, Treves TA, Drory M, Verchovsky R, Klimovitsky S, Ben-Laish S, Yaron S, Ginzburg K, Korczyn AD: Demented patients' participation in a clinical trial: factors affecting the caregivers' decision. Int J Geriatr Psychiatry. 2000, 15: 325-330. 10.1002/(SICI)1099-1166(200004)15:4<325::AID-GPS117>3.0.CO;2-9.CrossRefPubMed
29.
go back to reference Mastwyk M, Macfarlane S, LoGiudice D, Sullivan KA: Why participate in an Alzheimer's disease clinical trial? Is it of benefit to carers and patients?. Int Psychogeriatr. 2003, 15: 149-156. 10.1017/S1041610203008834.CrossRefPubMed Mastwyk M, Macfarlane S, LoGiudice D, Sullivan KA: Why participate in an Alzheimer's disease clinical trial? Is it of benefit to carers and patients?. Int Psychogeriatr. 2003, 15: 149-156. 10.1017/S1041610203008834.CrossRefPubMed
30.
go back to reference Mastwyk M, Ritchie CW, LoGiudice D, Sullivan KA, Macfarlane S: Carer impressions of participation in Alzheimer's disease clinical trials: what are their hopes? And is it worth it?. Int Psychogeriatr. 2002, 14: 39-45. 10.1017/S1041610202008268.CrossRefPubMed Mastwyk M, Ritchie CW, LoGiudice D, Sullivan KA, Macfarlane S: Carer impressions of participation in Alzheimer's disease clinical trials: what are their hopes? And is it worth it?. Int Psychogeriatr. 2002, 14: 39-45. 10.1017/S1041610202008268.CrossRefPubMed
31.
go back to reference Karlawish J, Cary MS, Rubright J, Tenhave T: How redesigning AD clinical trials might increase study partners' willingness to participate. Neurology. 2008, 71: 1883-1888. 10.1212/01.wnl.0000336652.05779.ea.PubMedCentralCrossRefPubMed Karlawish J, Cary MS, Rubright J, Tenhave T: How redesigning AD clinical trials might increase study partners' willingness to participate. Neurology. 2008, 71: 1883-1888. 10.1212/01.wnl.0000336652.05779.ea.PubMedCentralCrossRefPubMed
32.
go back to reference Brodaty H, Green A: Defining the role of the caregiver in Alzheimer's disease treatment. Drugs Aging. 2002, 19: 891-898. 10.2165/00002512-200219120-00001.CrossRefPubMed Brodaty H, Green A: Defining the role of the caregiver in Alzheimer's disease treatment. Drugs Aging. 2002, 19: 891-898. 10.2165/00002512-200219120-00001.CrossRefPubMed
33.
go back to reference Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC: The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999, 14: 701-710. 10.1002/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-#.CrossRefPubMed Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC: The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999, 14: 701-710. 10.1002/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-#.CrossRefPubMed
34.
go back to reference Grafstrom M, Winblad B: Family burden in the care of the demented and nondemented elderly--a longitudinal study. Alzheimer Dis Assoc Disord. 1995, 9: 78-86. 10.1097/00002093-199509020-00004.CrossRefPubMed Grafstrom M, Winblad B: Family burden in the care of the demented and nondemented elderly--a longitudinal study. Alzheimer Dis Assoc Disord. 1995, 9: 78-86. 10.1097/00002093-199509020-00004.CrossRefPubMed
35.
go back to reference Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005, 62: 753-757. 10.1001/archneur.62.5.753.CrossRefPubMed Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005, 62: 753-757. 10.1001/archneur.62.5.753.CrossRefPubMed
36.
go back to reference Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, Raskind M, Peskind E, Newhouse P, Sack D, De Souza E, Sadowsky C, Roberts E, DHEA-Alzheimer's Disease Collaborative Research: DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology. 2003, 60: 1071-1076.CrossRefPubMed Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, Raskind M, Peskind E, Newhouse P, Sack D, De Souza E, Sadowsky C, Roberts E, DHEA-Alzheimer's Disease Collaborative Research: DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology. 2003, 60: 1071-1076.CrossRefPubMed
37.
go back to reference Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003, 289: 2819-2826. 10.1001/jama.289.21.2819.CrossRefPubMed Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003, 289: 2819-2826. 10.1001/jama.289.21.2819.CrossRefPubMed
38.
go back to reference Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Group: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005, 352: 2379-2388. 10.1056/NEJMoa050151.CrossRefPubMed Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Group: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005, 352: 2379-2388. 10.1056/NEJMoa050151.CrossRefPubMed
39.
go back to reference Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010, 74: 956-964. 10.1212/WNL.0b013e3181d6476a.CrossRefPubMed Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010, 74: 956-964. 10.1212/WNL.0b013e3181d6476a.CrossRefPubMed
40.
go back to reference Edland SD, Emond JA, Aisen PS, Petersen RC: NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010, 24: 159-164. 10.1097/WAD.0b013e3181c9983f.PubMedCentralCrossRefPubMed Edland SD, Emond JA, Aisen PS, Petersen RC: NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010, 24: 159-164. 10.1097/WAD.0b013e3181c9983f.PubMedCentralCrossRefPubMed
41.
go back to reference Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001, 15: 169-173. 10.1097/00002093-200110000-00002.CrossRefPubMed Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001, 15: 169-173. 10.1097/00002093-200110000-00002.CrossRefPubMed
42.
go back to reference Helmer C, Peres K, Letenneur L, Guttierez-Robledo LM, Ramaroson H, Barberger-Gateau P, Fabrigoule C, Orgogozo JM, Dartigues JF: Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord. 2006, 22: 87-94. 10.1159/000093459.CrossRefPubMed Helmer C, Peres K, Letenneur L, Guttierez-Robledo LM, Ramaroson H, Barberger-Gateau P, Fabrigoule C, Orgogozo JM, Dartigues JF: Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord. 2006, 22: 87-94. 10.1159/000093459.CrossRefPubMed
43.
go back to reference Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003, 60: 1119-1122. 10.1001/archneur.60.8.1119.CrossRefPubMed Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003, 60: 1119-1122. 10.1001/archneur.60.8.1119.CrossRefPubMed
44.
go back to reference Schneider LS, Olin JT, Lyness SA, Chui HC: Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997, 45: 923-928.CrossRefPubMed Schneider LS, Olin JT, Lyness SA, Chui HC: Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997, 45: 923-928.CrossRefPubMed
45.
go back to reference Treves TA, Verchovsky R, Klimovitsky S, Korczyn AD: Recruitment rate to drug trials for dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2000, 14: 209-211. 10.1097/00002093-200010000-00004.CrossRefPubMed Treves TA, Verchovsky R, Klimovitsky S, Korczyn AD: Recruitment rate to drug trials for dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2000, 14: 209-211. 10.1097/00002093-200010000-00004.CrossRefPubMed
46.
go back to reference Schindler RJ: Study design considerations: conducting global clinical trials in early Alzheimer's disease. J Nutr Health Aging. 2010, 14: 312-314. 10.1007/s12603-010-0071-4.CrossRefPubMed Schindler RJ: Study design considerations: conducting global clinical trials in early Alzheimer's disease. J Nutr Health Aging. 2010, 14: 312-314. 10.1007/s12603-010-0071-4.CrossRefPubMed
47.
go back to reference Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA: Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009, 360: 816-823. 10.1056/NEJMsb0803929.CrossRefPubMed Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA: Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009, 360: 816-823. 10.1056/NEJMsb0803929.CrossRefPubMed
48.
go back to reference Homma A: Current status of clinical trials for Alzheimer-type dementia in Japan: strategies to facilitate the development of antidementia drugs. Alzheimer Dis Assoc Disord. 2000, 14 (Suppl 1): S123-126.CrossRefPubMed Homma A: Current status of clinical trials for Alzheimer-type dementia in Japan: strategies to facilitate the development of antidementia drugs. Alzheimer Dis Assoc Disord. 2000, 14 (Suppl 1): S123-126.CrossRefPubMed
49.
go back to reference Gold M: Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007, 68: 430-438. 10.4088/JCP.v68n0313.CrossRefPubMed Gold M: Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007, 68: 430-438. 10.4088/JCP.v68n0313.CrossRefPubMed
52.
go back to reference Fox S: Older Americans and the internet. 2004 Project Report. 2004, Washington, DC: The Pew Internet & American Life Project Fox S: Older Americans and the internet. 2004 Project Report. 2004, Washington, DC: The Pew Internet & American Life Project
53.
go back to reference Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ: Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010, 6: 89-97. 10.1016/j.jalz.2010.01.008.PubMedCentralCrossRefPubMed Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ: Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010, 6: 89-97. 10.1016/j.jalz.2010.01.008.PubMedCentralCrossRefPubMed
54.
go back to reference Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005, 30: 1204-1215. 10.1038/sj.npp.1300690.CrossRefPubMed Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005, 30: 1204-1215. 10.1038/sj.npp.1300690.CrossRefPubMed
55.
go back to reference Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R: Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007, 6: 501-512. 10.1016/S1474-4422(07)70109-6.CrossRefPubMed Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R: Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007, 6: 501-512. 10.1016/S1474-4422(07)70109-6.CrossRefPubMed
56.
go back to reference Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS: Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008, 70: 2024-2035. 10.1212/01.wnl.0000303815.69777.26.CrossRefPubMed Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS: Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008, 70: 2024-2035. 10.1212/01.wnl.0000303815.69777.26.CrossRefPubMed
57.
go back to reference Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S: Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004, 63: 651-657.CrossRefPubMed Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S: Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004, 63: 651-657.CrossRefPubMed
58.
go back to reference Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK: Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009, 72: 1555-1561. 10.1212/01.wnl.0000344650.95823.03.CrossRefPubMed Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK: Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009, 72: 1555-1561. 10.1212/01.wnl.0000344650.95823.03.CrossRefPubMed
59.
go back to reference Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-215. 10.1016/S0140-6736(08)61074-0.CrossRefPubMed Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-215. 10.1016/S0140-6736(08)61074-0.CrossRefPubMed
60.
go back to reference Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG: Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology. 2003, 61: 1498-1502.CrossRefPubMed Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG: Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology. 2003, 61: 1498-1502.CrossRefPubMed
61.
go back to reference Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562. 10.1212/01.WNL.0000159740.16984.3C.CrossRefPubMed Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562. 10.1212/01.WNL.0000159740.16984.3C.CrossRefPubMed
62.
go back to reference Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008, 65: 1031-1038. 10.1001/archneur.65.8.1031.PubMedCentralCrossRefPubMed Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008, 65: 1031-1038. 10.1001/archneur.65.8.1031.PubMedCentralCrossRefPubMed
63.
go back to reference Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R: IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007, 69: S14-22. 10.1212/01.wnl.0000281847.17519.e0.CrossRefPubMed Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R: IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007, 69: S14-22. 10.1212/01.wnl.0000281847.17519.e0.CrossRefPubMed
64.
go back to reference Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R: A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007, 22: 456-467. 10.1002/gps.1788.CrossRefPubMed Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R: A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007, 22: 456-467. 10.1002/gps.1788.CrossRefPubMed
65.
go back to reference Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6: 246-254.PubMed Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6: 246-254.PubMed
66.
go back to reference Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ: High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008, 300: 1774-1783. 10.1001/jama.300.15.1774.PubMedCentralCrossRefPubMed Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ: High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008, 300: 1774-1783. 10.1001/jama.300.15.1774.PubMedCentralCrossRefPubMed
67.
go back to reference van Dyck CH, Tariot PN, Meyers B, Malca Resnick E: A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007, 21: 136-143. 10.1097/WAD.0b013e318065c495.CrossRefPubMed van Dyck CH, Tariot PN, Meyers B, Malca Resnick E: A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007, 21: 136-143. 10.1097/WAD.0b013e318065c495.CrossRefPubMed
68.
go back to reference Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S: Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007, 69: 459-469. 10.1212/01.wnl.0000266627.96040.5a.CrossRefPubMed Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S: Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007, 69: 459-469. 10.1212/01.wnl.0000266627.96040.5a.CrossRefPubMed
69.
go back to reference Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000, 54: 2269-2276.CrossRefPubMed Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000, 54: 2269-2276.CrossRefPubMed
70.
go back to reference Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000, 54: 2261-2268.CrossRefPubMed Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000, 54: 2261-2268.CrossRefPubMed
71.
go back to reference Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997, 336: 1216-1222. 10.1056/NEJM199704243361704.CrossRefPubMed Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997, 336: 1216-1222. 10.1056/NEJM199704243361704.CrossRefPubMed
72.
go back to reference Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001, 57: 613-620.CrossRefPubMed Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001, 57: 613-620.CrossRefPubMed
Metadata
Title
Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials
Authors
Joshua D Grill
Jason Karlawish
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 6/2010
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/alzrt58